Ani Biome lands LongeVC backing to boost longevity via the microbiome

Longevity company develops personalized approaches to improve gut microbiome function and combat inflammation.

Metabolites-as-medicine company Ani Biome has secured an undisclosed investment from longevity focused investment firm, LongeVC. Co-founded by Nika Pintar and Bruno Balen, the company is focused on enhancing gut health to promote human longevity.

My take on this: Ani Biome uses machine learning models to provide personalized solutions for enhancing gut microbiome function and addressing inflammation, a prevalent factor in age-related chronic ailments. Employing a digital platform, the company offers non-invasive assessments and tailors naturally derived AgeBiotics molecules to individual requirements.

“Ani Biome combines a novel approach to AI with microbiome science to deliver personalised care,” said Sergey Jakimov, managing partner at LongeVC. “This investment aligns with our fund’s focus on biotech, which reinvents healthcare practices and outcomes. Ani Biome’s approach does this and brings us closer to a future where treatment is aligned with individual requirements and data.”

Ani Biome‘s approach is designed to promote short-chain fatty acid (SCFA) production within the gut, leveraging it as an “internal bioreactor” to mitigate low-grade chronic inflammation. The company’s app provides daily gut health monitoring and employs generative AI for emotional state tracking through proprietary tongue scans and a graph database.

Discover Ani Biome's latest partnership and future efforts, straight from LongeVC's Sergey Jakimov right HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!